Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name BTK C481S
Gene Variant Detail

BTK C481S (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BTK C481S diffuse large B-cell lymphoma sensitive ARQ 531 Preclinical - Cell culture Actionable In a preclinical study, ARQ 531 treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK C481S in culture (PMID: 35196427). 35196427
BTK C481S diffuse large B-cell lymphoma sensitive NX-2127 Preclinical - Cell line xenograft Actionable In a preclinical study, NX-2127 inhibited proliferation of a diffuse large B-cell lymphoma cell line expressing BTK C481S in culture, and resulted in tumor growth inhibition in a cell line xenograft model (62nd ASH Annual Meeting and Exposition, Dec 2020, Abstract 2788). detail...
BTK C481S diffuse large B-cell lymphoma sensitive Fenebrutinib Preclinical - Cell culture Actionable In a preclinical study, Fenebrutinib (GDC-0853) treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK C481S in culture (PMID: 35196427). 35196427
BTK C481S diffuse large B-cell lymphoma sensitive Ibrutinib + Venetoclax Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S resulting in Imbruvica (ibrutinib) resistance demonstrated increased sensitivity to Imbruvica (ibrutinib) when also treated with Venclexta (venetoclax), demonstrating decreased cell growth in culture (PMID: 28428442). 28428442
BTK C481S diffuse large B-cell lymphoma sensitive Vecabrutinib Preclinical - Cell culture Actionable In a preclinical study, Vecabrutinib (SNS-062) treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK C481S in culture (PMID: 35196427). 35196427
BTK C481S lymphoma resistant Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, lymphoma cells expressing BTK C481S were resistant to Imbruvica (ibrutinib) in culture (PMID: 27626698) 27626698
BTK C481S Advanced Solid Tumor predicted - sensitive RN486 Preclinical - Biochemical Actionable In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK C481S in culture (PMID: 33526860). 33526860
BTK C481S mantle cell lymphoma predicted - resistant Edralbrutinib Preclinical - Cell culture Actionable In a preclinical study, Edralbrutinib (TG-1701) treatment resulted in reduced sensitivity in a mantle cell lymphoma cell line expressing BTK C481S compared to the parental wild-type BTK cell line in culture (PMID: 34551904). 34551904
BTK C481S chronic lymphocytic leukemia/small lymphocytic lymphoma resistant Zanubrutinib Guideline Actionable Brukinsa (zanubrutinib) is not indicated for use in patients with Imbruvica (ibrutinib)-refractory chronic lymphocytic leukemia/small lymphocytic lymphoma harboring BTK C481S (NCCN.org). detail...
BTK C481S diffuse large B-cell lymphoma resistant Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 35196427). 35196427
BTK C481S chronic lymphocytic leukemia predicted - sensitive Fenebrutinib Case Reports/Case Series Actionable In a Phase I trial, Fenebrutinib (GDC-0853) treatment resulted in clinical activity in patients with chronic lymphocytic leukemia harboring BTK C481S including one patient with a partial response with lymphocytosis and duration of response of 2.5 months and two patients with stable disease, each with a decrease in tumor size from baseline of -44.0% and -23.0% (PMID: 29560128; NCT01991184). 29560128
BTK C481S chronic lymphocytic leukemia predicted - resistant Venetoclax Case Reports/Case Series Actionable In a clinical case study, a patient with chronic lymphocytic leukemia who had relapsed on treatment with Imbruvica (ibrutinib) was treated with Venclexta (venetoclax), but progressed and was found to harbor BTK C481S (PMID: 32232486). 32232486
BTK C481S diffuse large B-cell lymphoma sensitive LOXO-305 Preclinical - Cell culture Actionable In a preclinical study, LOXO-305 treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK C481S in culture (PMID: 35196427). 35196427
BTK C481S Advanced Solid Tumor predicted - sensitive Fenebrutinib Preclinical - Biochemical Actionable In a preclinical study, treatment with Fenebrutinib resulted in reduced Btk activity in a cell line expressing BTK C481S in culture (PMID: 33526860). 33526860
BTK C481S chronic lymphocytic leukemia/small lymphocytic lymphoma resistant Acalabrutinib Guideline Actionable Calquence (acalabrutinib) is not indicated for use in patients with Imbruvica (ibrutinib)-refractory chronic lymphocytic leukemia/small lymphocytic lymphoma harboring BTK C481S (NCCN.org). detail...
BTK C481S hematologic cancer predicted - sensitive RXC005 Preclinical - Cell culture Actionable In a preclinical study, hematological cancer cell lines that are dependent on Btk signaling demonstrated sensitivity to RXC005 in culture (Blood 2016 128:4399). detail...
BTK C481S chronic lymphocytic leukemia sensitive ARQ 531 Preclinical - Patient cell culture Actionable In a preclinical study, ARQ 531 treatment inhibited activation of BCR signaling and induced cytotoxicity in Imbruvica (ibrutinib)-resistant patient-derived chronic lymphocytic leukemia cells harboring BTK C481S in culture (PMID: 30093506). 30093506
BTK C481S mantle cell lymphoma resistant Ibrutinib Case Reports/Case Series Actionable In a clinical study, BTK C418S was identified as an acquired mutation that confers resistance to Imbruvica (ibrutinib) in two patients with mantle cell lymphoma who relapsed after a durable response (PMID: 25082755). 25082755
BTK C481S chronic lymphocytic leukemia resistant Ibrutinib Clinical Study - Cohort Actionable In a clinical study, BTK C418S was identified as an acquired mutation that confers resistance to Imbruvica by preventing irreversible binding of ibrutinib to BTK in patients with chronic lymphocytic leukemia who relapsed while on Imbruvica (ibrutinib)(PMID: 24869598). 24869598
BTK C481S chronic lymphocytic leukemia resistant Ibrutinib Preclinical - Patient cell culture Actionable In a preclinical study, primary chronic lymphocytic leukemia cells derived from patients who acquired BTK C481S following Imbruvica (ibrutinib) treatment demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 30093506). 30093506
BTK C481S diffuse large B-cell lymphoma activated B-cell type predicted - sensitive NX-5948 Preclinical - Cell line xenograft Actionable In a preclinical study, NX-5948 treatment resulted in degradation of BTK C481S and inhibited proliferation of an activated B-cell type diffuse large B-cell lymphoma (ABC-DLBCL) cell line harboring BTK C481S in culture and inhibited tumor growth in a cell line xenograft model (Blood 2021 138 (Supp 1):2251). detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries